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Abstract
PURPOSE—To assess the association between single nucleotide polymorphisms (SNPs) of the
gene region containing cyclin dependent kinase inhibitor 2B antisense noncoding RNA
(CDKN2B-AS1) and glaucoma features among primary open-angle glaucoma (POAG) patients.
DESIGN—Retrospective observational case series.
METHODS—We studied associations between ten CDKN2B-AS1 SNPs and glaucoma features
among 976 POAG cases from the Glaucoma Genes and Environment (GLAUGEN) study and
1971 cases from the National Eye Institute Glaucoma Human Genetics Collaboration
(NEIGHBOR) consortium. For each patient, we chose the feature from the eye with the higher
value. We created cohort-specific multivariable models for glaucoma features and then meta-
analyzed the results.
RESULTS—For nine of the ten protective CDKN2B-AS1 SNPs with minor alleles associated
with reduced disease risk (e.g., the G allele at rs2157719), POAG patients carrying these minor
alleles had smaller cup-disc ratio (0.05 units smaller per G allele at diagnosis; 95% CI: −0.08,
−0.03; p=6.23E-05) despite having higher intraocular pressure (IOP) (0.70 mm Hg higher per G
allele at DNA collection; 95% CI: 0.40, 1.00; P=5.45E-06). For the one adverse rs3217992 SNP
with minor allele A associated with increased disease risk, POAG patients with A alleles had
larger cup-disc ratio (0.05 units larger per A allele at diagnosis; 95% CI: 0.02, 0.07; P=4.74E-04)
despite having lower IOP (−0.57 mm Hg per A allele at DNA collection; 95% CI: −0.84, −0.29;
P=6.55E-05).
CONCLUSION—Alleles of CDKN2B-AS1 SNPs, which influence risk of developing POAG,
also modulate optic nerve degeneration among POAG patients, underscoring the role of
CDKN2B-AS1 in POAG.
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The cyclin dependent kinase inhibitor 2B antisense noncoding RNA (CDKN2B-AS1)
genomic region on chromosome 9p21.3 is a genetic susceptibility locus for several age-
related complex diseases (for an explanation of genetic terminology used in this manuscript
see Table 1).1 Genome-wide association (GWA) studies and candidate gene investigations
indicate that gene variants in this region are associated with primary open-angle glaucoma
(POAG) but the relation between CDKN2B-AS1 genetic variants and specific glaucoma
features are not well known.2–7 CDKN2B-AS1 is an antisense RNA that may influence the
nearby CDKN2A (cyclin dependent kinase inhibitor 2A) and CDKN2B (cyclin dependent
kinase inhibitor 2B) genes via regulatory mechanisms.8 CDKN2A and CDKN2B, which are
expressed in all cell types, influence cell proliferation9,10 and senescence.11–14 Retinal
ganglion cells (RGCs), a target for degeneration in POAG, must maintain a quiescent post-
mitotic state for an indefinite period in order to carry out their physiologic functions. In
POAG, elevated intraocular pressure (IOP) and other insults may trigger quiescent RGCs to
undergo apoptosis.15,16
Sequence variants in CDKN2B-AS1 are associated with cup-disc ratio in a normal
population.17 Interestingly, common minor alleles for several of these variants are
associated with a smaller cup-disc ratio in normal subjects,17 as well as a reduced risk of
POAG.2–7 Cup-disc ratio is a structural optic nerve feature highly correlated with the POAG
disease process. POAG is a form of deleterious optic nerve aging without obvious secondary
cause that is exacerbated by intraocular pressure (IOP) and ultimately results in functional
visual loss.
In this study we used the data from POAG cases enrolled in two large case-control groups
where GWA studies have been completed: the GLAUGEN (Glaucoma Genes and
Environment) study, part of the GENEVA (the Gene, Environment Association Studies)
consortium18 and the NEIGHBOR (National Eye Institute Glaucoma Human Genetics
Collaboration) consortium.19 In order to gain further insight regarding the CDKN2B-AS1
genomic region and the glaucomatous process, we assessed the association between ten
CDKN2B-AS1 single nucleotide polymorphisms (SNPs) strongly associated with POAG
and glaucoma features like age at diagnosis, IOP parameters, cup-disc ratio, visual field
parameters, and the need for laser trabeculoplasty (LTP) or incisional surgery.
METHODS
The Institutional Review Boards of Mass Eye and Ear Infirmary, Brigham and Women’s
Hospital, Harvard School of Public Health as well as the Institutional Review Boards of the
participating NEIGHBOR institutions prospectively approved the genotyping efforts, data
analyses and data sharing arrangements described herein. Each participant gave written
consent to participate in this observational case series.
Description of the study populations
The GLAUGEN study consists of POAG cases and controls drawn from the Nurses’ Health
Study (NHS), the Health Professionals Follow-up Study (HPFS) and the Genetic Etiologies
of Primary Open-Angle Glaucoma study (GEP). The former two studies are population-
based, nested case-control studies and the latter study is a clinic-based, case-control study
from the Massachusetts Eye and Ear Infirmary (MEEI). Details regarding the inclusion/
exclusion criteria for the GLAUGEN POAG case-control cohort have been described
(www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000308.v1.p1).
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The NEIGHBOR consortium consists of POAG cases and controls from twelve sites. Details
regarding the study sites, design, inclusion criteria and clinical variables collected in the
NEIGHBOR consortium have also been described elsewhere.19
Case definition
All cases had slit lamp examinations, which did not reveal secondary cause of elevated IOP
(such as exfoliation syndrome) and the anterior chamber angle was deemed non-occludable.
We did not employ IOP criteria in defining POAG. All cases had either reproducible visual
field (VF) loss or one abnormal VF associated with cup-disc ratio > 0.7 in the eye with loss.
Reproducible VF loss consistent with nerve fiber layer pathology had to be demonstrated on
tests that were considered reliable (fixation loss ≤33%, false positive rate ≤20% and false
negative rate ≤20%). We categorized the observed VF loss depending on whether it
involved the paracentral zone, nasal step region, Bjerrum’s area and the temporal wedge
region above and/or below the horizontal meridian based on a systemic evaluation of the
pattern deviation plot or its equivalent. There was no restriction placed on the type of VF
perimeter used.
Genotyping data
Details regarding DNA collection, extraction, and plating for GLAUGEN20 and
NEIGHBOR5 have been previously described. We used the Illumina Human660W-Quad-v1
array (Illumina; San Diego, CA) for high throughput genotyping. Both sets of genotyping
data were subject to extensive quality control checks that have been previously
described.5,20
Gene association analyses and the 9p21 polymorphisms chosen for analysis
After employing quality control filters, gene association analyses in GLAUGEN and
NEIGHBOR were performed using PLINK v1.07.21 Details regarding these analyses have
been described elsewhere.5,20 Briefly, in GLAUGEN among 976 cases and 1140 controls,
no genetic loci achieved genome-wide significant association with POAG. In NEIGHBOR,
among 2170 cases and 2347 controls, 17 SNPs reached genome-wide significance
(p≤5E-08), 16 of which were in the CDKN2B-AS1 region.5 The top SNP associated with
POAG was rs4977756 (Odds Ratio=0.66; 95% CI: 0.59–0.73; p=7.4E-16). Using METAL,
we performed a meta-analysis of the GLAUGEN and NEIGHBOR dataset and identified 19
SNPs with genome-wide significant associations in relation to POAG, and 17 of these were
in the CDKN2B-AS1 region. In this study of POAG phenotypes, we chose to analyze the
top ten CDKN2B-AS1 SNPs associated with POAG in the meta–analysis. The effect sizes,
p-values and risk alleles for the chosen SNPs in relation to POAG are provided in the
supplemental Table.
Ascertainment of glaucoma phenotype features
We required that all cases included in our study have data on age at diagnosis (Table 2). It
can be difficult to ascertain age at diagnosis for POAG, as it is an insidious onset disease;
yet, the determination of whether CDKN2B-AS1 variants are associated with this glaucoma
feature is important because an earlier age of diagnosis could translate into more visual
disability from the condition later in life. Age at diagnosis in GLAUGEN and in
NEIGHBOR was defined as the age at first sign of disease, namely, cup-disc ratio >0.6, cup-
disc ratio asymmetry ≥0.2, IOP >21 mm Hg, or VF loss which was ascertained based on
medical record review.
The IOP recorded was either at the time of diagnosis or at DNA collection (which was
typically after diagnosis and while under treatment especially for NEIGHBOR participants).
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We also recorded whether there was a history of IOP > 21 mm Hg or the highest known IOP
when such data was available. Similarly, cup-disc ratio recorded was either at diagnosis or at
DNA collection. The type of IOP and cup-disc ratio data available varied by study subtype.
Specifically, IOP and cup-disc ratio at diagnosis were available for NHS and HPFS cases in
GLAUGEN. We excluded all NEIGHBOR cases from the assessment of CDKN2AB-AS1
SNPs in relation to IOP and cup-disc ratio at diagnosis as continuous variables because these
features were only available in the Collaborative Initial Glaucoma Treatment Study
(www.clinicaltrials.gov; NCT00000149) site. Nonetheless, a history of IOP ≥ 22 mm Hg at
diagnosis was available on all NEIGHBOR participants. IOP and cup-disc ratio at DNA
collection were available among MEEI cases in GLAUGEN and all NEIGHBOR cases
except the Johns Hopkins University (JHU) and CIGTS sites. At the JHU site of
NEIGHBOR, the collected IOPs represent the highest known values. For all study sites, the
higher values between eyes were chosen for analysis. Box plots depicting the distribution of
IOPs and cup-disc ratio by study site are provided in Supplemental Figures 1 and 2. Median
IOP was >21 mm Hg in NHS, HPFS, CIGTS, the Advanced Glaucoma Intervention Study
(AGIS; www.clinicaltrials.gov; NCT00000148) site and the JHU cases. For all other sites,
the median IOP ranged between 15 and 18 mm Hg. Median cup-disc ratios ranged between
0.6–0.7 for sites with incident cases (NHS and HPFS in GLAUGEN and CIGTS in
NEIGHBOR) and 0.8–0.9 across study centers with mostly prevalent cases (MEEI in
GLAUGEN and West Virginia University, University of Pittsburgh, JHU, Stanford
University, Duke University, University of Michigan, AGIS and Marshfield Clinic in
NEIGHBOR). Since age at diagnosis was unavailable at the University of Miami site, these
cases were excluded from all CDKN2B-AS1 – glaucoma feature analyses.
For the VF global indices, mean defect (MD) and pattern standard deviation (PSD), we
chose the parameter from the eye showing more functional loss on the earliest available
Humphrey VF test. A glaucoma specialist (LRP) reviewed all VF tests and excluded cases
judged to have non-glaucomatous loss (such as age-related macular degeneration) or lens
rim artifact from CDKN2B-AS1 genotype - correlations analysis with MD, PSD and pattern
of VF loss. Furthermore, because PSD begins to decline with severe generalized reduction
of retinal sensitivity,22 we excluded patients with MD values worse than −13 dB in the
analysis of the relation between CDKN2B-AS1 SNPs and PSD (47 exclusions in
GLAUGEN and 238 in NEIGHBOR). This cutoff was chosen based on inspection of a
graph of MD vs. PSD using the earliest available VF from NEIGHBOR and GLAUGEN
participants (data not shown).
VFs were classified as having ‘peripheral VF loss only’ if the paracentral zone was not
involved. In contrast, VFs were categorized as having ‘paracentral VF loss only’ if the nasal
step regions, Bjerrum areas and temporal wedge areas were not involved. Furthermore, VFs
were classified as having ‘superior VF loss only’ if the inferior hemifield of the pattern
deviation plot was normal. The opposite was true for VF with ‘inferior VF loss only’. We
also classified patients with ‘paracentral and peripheral loss’ and patients with ‘superior and
inferior loss.’
In GLAUGEN we collected data on a history of LTP and incisional glaucoma surgery of any
kind. In NEIGHBOR this data was only available on from the CIGTS and the AGIS sites.
Since these procedures were performed as part of randomized clinical trials in CIGTS23 and
AGIS24, these data on laser and incisional surgery were excluded from genotype-phenotype
correlations.
Statistical analysis
We created multivariable linear regression models for continuous phenotypes and multiple
logistic regression models for categorical phenotypes using SAS9.2 (Cary, NC). CDKN2B-
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AS1 SNPs were coded as minor allele dose variables with 3 values: 0=no minor allele, 1=1
minor allele, and 2=2 minor alleles. We first analyzed the data from GLAUGEN and
NEIGHBOR separately and performed tests for heterogeneity to check for appropriateness
of pooling the results. When appropriate, we pooled the results using meta-analytic
methods.25 We adjusted for variables that influenced genotyping call rates (which were all
>98% in both studies): DNA source (blood or cheek), study site (NHS, HPFS or GEP in
GLAUGEN or the study subsite in NEIGHBOR), and the method of DNA extraction
(GENTRA, DNAzol or QIAGEN). We also adjusted the relation between genotypes and
glaucoma features for population structure (a genetic surrogate of ancestry) using 3
eigenvectors in GLAUGEN and 2 eigenvectors in NEIGHBOR. Finally we also adjusted for
age at diagnosis (expect when this was the outcome of interest) and gender in all models.
We used the Bonferroni correction, accounting for the number of unique linkage
disequilibrium (LD) blocks where our SNPs were located (five blocks; see Supplemental
Figure 3) and the number of unique glaucoma features we assessed as outcomes (ten), to
establish p-values <0.001 as statistically significant.
In secondary analyses assessing the association of CDKN2B-AS1 SNPs with CDR
parameters, we additionally controlled for atonal homolog 7 (ATOH7) SNPs (rs7916697
and rs3858145) strongly correlated with disc area.17,26 For associations between CDKN2B-
AS1 SNPs that showed statistically significant associations with VF parameters, we further
adjusted for cup-disc ratio. Finally, since age at diagnosis can depend on IOP level but IOP
criteria were not employed in diagnosing glaucoma, we performed a secondary analysis of
the relation between CDKN2B-AS1 and age at diagnosis among cases with no history of
IOP ≥ 22 mm Hg.
RESULTS
The 976 GLAUGEN patients and 1971 NEIGHBOR patients for whom we recorded the age
at diagnosis represents 100% and 90.8% of the POAG cases respectively that completed
high throughput genotyping in these cohorts. Tables 2 and 3 summarize the demographic
and ocular features for POAG cases. The mean age at diagnosis was slightly less in
GLAUGEN than in NEIGHBOR. The minimal age at diagnosis in these studies corresponds
to the minimal age criteria for inclusion in the respective studies. As expected, mean IOP at
diagnosis was higher than the mean IOP at DNA collection because the former represented
untreated levels (Table 2). Similarly, the CDR at diagnosis was smaller than the cup-disc
ratio at DNA collection because the latter came from prevalent cases. While VF loss was
required for all cases, MD values were only available for 87% and 69% of GLAUGEN and
NEIGHBOR cases respectively because not all subjects had Humphrey VFs. Table 3 also
shows the percent of patients with the various types of VF loss patterns.
The LD block structure for the CDKN2B-AS1 SNPs is provided in Supplemental Figure 3.
The minor allele for the most upstream SNP (rs32177992) is associated with increased
POAG risk; the remainder are associated with decreased POAG risk.5
Table 4 provides data for the associations between each minor allele for CDKN2B-AS1
SNPs and continuous glaucoma features after meta-analysis of the GLAUGEN and
NEIGHBOR data. Table 5 shows the associations between each minor allele for the
CDKN2B-AS1 SNPs and dichotomous glaucoma features determined by meta-analysis.
9p21 polymorphisms in relation to age at diagnosis / intraocular pressure variables in
primary open-angle glaucoma cases
There was no significant association between any CDKN2B-AS1 SNP and age at glaucoma
diagnosis (n=2,947 cases; Table 4). In secondary analysis limited to cases with IOP < 22
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mm Hg (n=573 cases), one SNP (rs573687) was significantly associated with a later age at
diagnosis after accounting for the multiple comparisons made. This SNP was associated
with a reduced risk of POAG in our case-control study. Each minor allele (A) in this SNP
was associated with developing disease 4.5 years later (95% CI: 2.04, 10.1 years; p=0.0002)
than people who were homozygous for the reference genotype (GG). There was no
significant association between any CDKN2B-AS1 SNPs and IOP at diagnosis (n=345
cases; Table 4). However, there were associations between CDKN2B-AS1 SNPs and a
history of IOP > 21 mm Hg at diagnosis, which was available for a larger group of cases
(n=2,195; Table 5). For example, for rs1063192, which is inversely related to POAG, there
was a 39% increased risk of IOP > 21 mm Hg at diagnosis (95% CI: 1.17, 1.66;
p=2.00E-04) per minor allele (Table 5). Similar trends were seen for three other SNPs that
were associated with reduced risk of POAG. On the other hand, for each additional minor
allele of rs3217992, which is associated with increased POAG risk, IOP at DNA collection
was 0.57 mm Hg lower per minor allele (95% CI: −0.84, −0.29 mm Hg; p=6.55E-05) (Table
4; n=1,942 cases). The associations between CDKN2B-AS1 SNPs and IOP at DNA
collection remained after excluding cases with a history of incisional glaucoma surgery
(p≤1.61E-04; data not shown).
9p21 polymorphisms in relation to cup-disc ratio variables
POAG cases with protective CDKN2B-AS1 alleles tended to have smaller cup-disc ratio at
diagnosis (0.05–0.06 units lower per minor allele; p≤1.96E-04; n=458) than cases
homozygous for the common reference genotypes (Table 4). Conversely, cases with minor
alleles for the adverse SNP (rs32177992), had larger cup-disc ratio at diagnosis (Table 4).
The statistically significant results remained even after adjustment for SNPs associated with
disc size in ATOH7 (p≤3.85E-04; data not shown). Similar trends were observed when cup-
disc ratio at diagnosis was treated as a dichotomous variable (>0.6 or ≤0.6) but the results
were not significant after adjusting for multiple comparisons (Table 5). There were no
associations between CDKN2B-AS1 SNPs and cup-disc ratio at the time of DNA collection
using either linear regression (Table 4) or logistic regression (Table 5) models.
9p21 polymorphisms in relation to visual field features
We found no significant relation between CDKN2B-AS1 SNPs and MD from the earliest
Humphrey VFs using multivariable linear regression analysis (Table 4). However, among
cases with MD better than −13 dB, there were significant relationships between CDKN2B-
AS1 SNPs and PSD. For the SNP associated with increased POAG risk (rs3217992), each
minor allele was associated with a 0.50 dB higher PSD (95% CI: 0.30 dB, 0.71 dB;
p=1.50E-06). This association was essentially unchanged when additionally controlled for
cup-disc ratio at diagnosis in NHS and HPFS and cup-disc ratio at DNA collection for all
other participants (0.46 dB higher; 95% CI: 0.24 dB, 0.68 dB; p=5.35E-05). For the three
significant SNPs associated with decreased POAG risk (rs7049105, rs2151280 and
rs1012068), each minor allele was associated with a 0.35–0.36 dB lower PSD (p≤9.00E-04;
Table 4). While cases with minor alleles of selected protective CDKN2B-AS1 SNPs had
lower PSD, these latter associations were not significant after controlling for cup-disc ratio.
Interestingly, for each minor allele of rs3217992 (which was associated with increased
POAG risk), there was a 21% reduced risk of ‘peripheral VF loss only’ (95% CI: 0.70, 0.89;
p=1.00E-04). Conversely, for each minor allele of the protective SNP rs2157719, there was
a 24% increased risk of ‘peripheral VF loss only’ in one or both eyes (95% CI: 1.09–1.41;
p=9.00E-04). These associations were not significant after controlling for cup-disc ratio. No
other significant associations between CDKN2B-AS1 SNPs and pattern of VF loss were
detected.
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9p21 in relation to a history of laser trabeculoplasty and incisional glaucoma surgery
With data available on 976 GLAUGEN cases, we found no association between CDKN2B-
AS1 SNPs and a history of incisional glaucoma surgery among POAG cases (Table 5).
Similarly we did not find associations between CDKN2B-AS1 SNPs and a history of LTP
among POAG cases (data not shown).
DISCUSSION
POAG cases with the minor alleles in rs3217992 (which increases POAG risk) had larger
cup-disc ratio at diagnosis and a higher PSD on the earliest available VF manifesting
functional loss despite having lower IOP at DNA collection. In contrast, cases with minor
alleles in selected SNPs that reduce POAG risk had smaller cup-disc ratio at diagnosis and
increased chance of peripheral VF loss only on the earliest VF despite an increased IOP at
DNA collection. These data suggest that genotypes in the CDKN2B-AS1 region modulate
vulnerability to glaucoma. It is not surprising that POAG patients would harbor protective
CDKN2B-AS1 variants, as they are common among Caucasians and POAG is a polygenetic
disease modified by environmental influences.27,28
Age at diagnosis and history of incisional glaucoma surgery
We observed no significant associations between CDKN2B-AS1 SNP genotypes and age at
glaucoma diagnosis (n=2,947). Limiting analysis to cases where there was no known IOP ≥
22 mm Hg (n=573 cases), there was a SNP associated with a later age at diagnosis. As we
learn more about the genetic architecture of POAG, knowledge of genotypes that influence
age of disease onset among people with normal IOP and glaucoma-like discs may play a role
in optimizing glaucoma management. We found no relation between CDKN2B-AS1 SNP
genotype and history of incisional surgery among GLAUGEN cases. Only 15% of 976 cases
in this group required glaucoma filtration surgery, which might have limited the power to
detect modest associations between CDKN2B-AS1 SNPs and this glaucoma feature.
Furthermore the reasons to undergo surgery for this group of patients are heterogeneous and
likely transcend issues related solely to recalcitrance to medical therapy and LTP.
Nonetheless, this study suggests that CDKN2B-AS1 genotypes seem unrelated to a history
of incisional glaucoma surgery, a feature suggestive of increased risk of vision loss via
exposure to potential surgical complications.
Intraocular pressure variables
CDKN2B-AS1 SNPs were significantly associated with IOP at DNA collection in 1,942
cases, even though IOP levels at DNA collection were influenced by glaucoma treatment.
For example, POAG patients possessing protective CDKN2B-AS1 minor alleles had higher
IOP at DNA collection than patients who were homozygous for the corresponding more
common reference genotypes. Similar associations were observed between these same
alleles and IOP at diagnosis but the results were not statistically significant (n=345 cases)
perhaps reflecting the smaller sample size. The similar effect estimates for IOP at diagnosis
and at DNA collection probably reflect a correlation between untreated and treated IOP.29 In
contrast, POAG patients harboring the minor alleles in rs3217992 that predispose to disease
had lower IOP at DNA collection than patients who were homozygous for the more
common reference genotype. These data suggest that CDKN2B-AS1 SNPs modulate
susceptibility to IOP. There is already some data suggesting this effect could be generalized
to other glaucomas, as Wiggs et al. found rs2157719 is also associated with reduced risk of
exfoliation syndrome-related open angle glaucoma but not exfoliation syndrome alone.5
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Cup-disc ratio and visual field parameters
CDKN2B-AS1 SNPs were originally described in association with cup-disc ratio,17 raising
the question of whether this genomic region merely explains variance in normal optic nerve
structure or whether this region is associated with optic nerve pathology that is responsible
for the visual consequences seen in glaucoma. Variants protective against POAG were
associated with smaller cup-disc ratio at disease presentation while the opposite was true for
the adverse variant. Some of the same protective variants were also associated with smaller
cup-disc ratio in a large population from Rotterdam, most of which did not have
glaucoma.17
Because there is some correlation between cup-disc ratio (structure) and PSD (function)
(R=0.18; p≤0.0001 in GLAUGEN), we purposefully imposed an additional term for cup-
disc ratio in our model to assess the relation between CDKN2B-AS1 SNPs and PSD. While
most of the associations between CDKN2B-AS1 SNPs and PSD became insignificant, the
significant association between rs3217992 and PSD remained, suggesting this SNP renders
the optic nerve susceptible to focal nerve fiber layer dropout in POAG. Thus it seems
plausible that CDKN2B-AS1 variants explain both normal and pathologic changes in optic
nerve structure that produce functional consequences.
Finding genetic variants linked to incident paracentral visual loss is of utmost importance
because this pattern of loss places POAG patients at higher risk of developing visual
disability as the disease advances. We found no association between CDKN2B-AS1 allelic
variants and paracentral VF loss (n=214 cases with paracentral VF loss only). However, we
observed that the adverse SNP variants in rs3217992 were associated with a reduced risk of
peripheral VF loss only (n=950 cases). Conversely, the protective variants in rs2157719
were associated with an increased chance of peripheral VF loss only. The significance of
these statistical associations was attenuated when cup-disc ratio was additionally controlled
for; however, it is unclear if this represents a form of over controlling. It is possible that our
inability to find associations with paracentral VF loss could be due to lack of power, given
that only ~18% in GLAUGEN and 3% in NEIGHBOR had this glaucoma feature.
The unique strength of this study is its large sample size with 9p21 region genotypes and
glaucoma feature data available on up to 2,947 POAG cases from throughout the United
States. Shortcomings of the study include the fact that glaucoma feature information was
collected in a non-uniform manner and was missing for some cases. While this study was
limited entirely to Caucasians, it is interesting to inspect the minor allele frequency (MAF)
of the 9p21 gene region variants in the African population from Yoruba. The MAF of
CDKN2B-AS1 SNPs associated with smaller cup-disc ratio are generally much higher in
Caucasians than in African people (Supplemental Table) (www.ncbi.nlm.nih.gov/SNP;
dbSNP Build ID:37.3). For example, the allelic variant of rs2157719 which is associated
with reduced risk of POAG5 and a smaller CDR in POAG cases, has a MAF of 0.44 in
Caucasians but is rare in a African population from Nigeria (MAF=0). Perhaps the relative
low mean allele frequencies of protective CDKN2B-AS1 alleles in African populations
overall explains the results of a recent study that showed normal Caucasians had more
favorable PSD values than normal African Americans on Humphrey VF tests.30 Several
studies also find larger cup-disc ratio in African people but this difference could reflect the
presence of a larger disc area.30–34 Interestingly, Cao et al. reported that the protective
relation between the minor allele in rs1063192 and POAG found in Caucasians3,5 is also
noted in an Afro-Caribbean population.35 The authors postulate that population admixture
may have increased the allele frequency of the minor allele for this SNP relative to sub-
Saharan Africans35 where this allele is virtually non-existent (see supplemental Table).
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In conclusion, in this US-based observational case study, we found associations between
9p21 variants and glaucoma features that suggest this region modifies optic nerve
vulnerability to glaucomatous change. In fact our CDKN2B-AS1 – glaucoma feature
correlations agree with the study published by Burdon et al.36 Our study provides further
support for the notion that the CDKN2B-AS1 region is important for maintaining RGCs in a
stable post-mitotic state. These data underscore the need to determine how CDKN2B-AS1
region gene variants impact RGC biology. As the genetic landscape for POAG becomes
clearer, knowledge of 9p21 region genotypes may be useful for optimizing glaucoma
management.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Explanation of genetic terminology used in this manuscript:
Allele –one member of a DNA sequence pair that contributes to a trait. DNA sequence is comprised of a string of the following bases: adenine
[A], guanine [G], cytosine [C] or thymine [T].
Antisense noncoding RNA –a single-strand RNA that does not result in protein translation; rather it can bind to nearby genes to alter their
expression.
CDKN2BAS - cyclin dependent kinase inhibitor 2B antisense RNA – a segment of DNA that generates noncoding RNA located near the
CDKN2B gene on chromosome 9.
Eigenvector – as it relates to an assessment of population structure, these are mathematically derived vectors representing a set of high
throughput genotypes into clusters that reflect ancestral tendencies.
Genotype – specifies the pair of alleles (1 paternal and 1 maternal) at any specific genomic location; for example the following genotypes are
possible at rs3217792 for CDKN2BAS: GG (wild type), GA, AA (homozygous genotype for the minor variant).
Genome wide association (GWA) study – a study of the relation between a series of gene variants strategically located throughout the genome
and a trait of interest (such as primary open-angle glaucoma).
Illumina Human660W-Quad-v1 array – a type of commercially available chip that allows for genotyping at 660,000 locations throughout the
human genome on a DNA sample.
Linkage disequilibrium block (LD block)- a region in the genome where a set of SNPs is non-randomly associated with each other. When the
genotype of one SNP in an LD block is known, the genotypes of the other SNPs in the block can be predicted with reasonable accuracy.
METAL – a contraction of meta analysis, refers to a statistical software tool to synthesis large datasets such as high throughout genotype data
from various sources in a computer memory efficient manner. For more information about METAL see www.sph.umich.edu/csg/abecasis/
Metal/
Minor allele frequency (MAF)/minor allele – refers to the frequency of occurrence of the less common allele (aka, the minor allele) when
single nucleotide differences exist between members of the same species. For example two individuals may contain the following sequence
variants: CGAACTA and CGAATTA. The underlined nucleotide represents a single nucleotide polymorphic site and if T is less common and
occurs 15% of the time, we say the MAF for T is 0.15.
PLINK - an open-source analysis toolset used to analyze high throughput genotyping data. For more information about PLINK see http://
pngu.mgh.harvard.edu/~purcell/plink/
rs numbers (also known as ref SNP numbers) – an assignment or address for a polymorphic site in the human genome. For example, rs3217792
resides in the CDKN2BAS region on chromosome 9p21. The major allele at this site is G present in ~63% of Caucasians and the minor allele at
this site is A present in 37% of Caucasians.
SNP- single nucleotide polymorphism – a substitute of one allele for another in the genome; these substitutions can be common or rare and may
or may not effect the function of the genomic segment in question. A common working hypothesis in genetic epidemiology research is that
common SNPs serve as risk factors for complex diseases that are not inherited in a Mendelian fashion. Consider three unrelated individuals with




The first base represents a polymorphic site or SNP in that the A allele is changed to a G allele for the third DNA sequence.
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Table 3
Demographic and ocular features of Glaucoma Genes and Environment (GLAUGEN) and National Eye
Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) cases with binary glaucoma feature
variables.
GLAUGEN NEIGHBOR
Variable % > cutoff N % > cutoff N
Age at diagnosis ≥ 65 years 49.3 976 56.5 1971
Gender (% female) 58.4 976 52.1 1971
Intraocular pressure ≥ 22 mm Hg at diagnosis 67.0 976 79.4 1219
Cup-disc ratio ≥ 0.6 at diagnosis 69.9 458 n/a n/a
Cup-disc ratio ≥ 0.6 at DNA collection 96.3 485 95.8 1611
Laser trabeculoplasty 28.2 976 36.8 38
Incisional glaucoma surgery 15.1 976 55.0 40
Pattern standard deviation ≥ 6 decibels 39.8 802 45.4 1119
Mean defect ≤ −13 decibels 14.6 849 26.6 1357
Peripheral visual field loss only* 52.1 963 31.5 1423
Paracentral visual field loss only * 17.9 963 3.0 1423
Both peripheral and paracentral visual field loss* 30.0 963 65.1 1423
Superior visual field loss only* 38.8 963 27.6 1423
Inferior visual field loss only* 30.3 963 21.2 1423
Both superior and inferior visual field loss* 28.8 963 50.7 1423
*
These visual field loss attributes are applied on a per patient basis. For instance, peripheral visual field loss only means that one or both eyes of a
patient have peripheral visual field loss and neither has paracentral field loss.
Abbreviations used: DNA= Deoxyribonucleic acid; n/a=not available
NB: Certain phenotype features were absent on some subsets of GLAUGEN and NEIGHBOR. We included data on CDR >0.6 at diagnosis from
the Nurses Health Study (NHS) and Health Professionals Follow-up Study (HPFS) subsets of GLAUGEN. We included data on CDR>0.6 at DNA
collection from the Mass Eye and Ear Infirmary (MEEI) subset of GLAUGEN and all NEIGHBOR sites. For laser trabeculoplasty and incisional
glaucoma surgery we included data from GLAUGEN as well as the Collaborative Initial Glaucoma Treatment Study and Advanced Glaucoma
Intervention Study sub sites of NEIGHBOR. Missing data for the visual field parameters (mean defects and pattern standard deviation) solely
reflects the fact that some participants had visual field tests other than Humphrey tests. Missing data for parameters related to the pattern of visual
loss (e.g. peripheral visual field loss only) occurred for several reasons including visual field loss was confounded from deficits not attributable to
glaucoma like age-related macula or tests assessed segments outside the range of the central 24 or 30 degrees.
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